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ABSTRACT
The protein phosphatase 2A (PP2A) is a key tumor suppressor which has emerged 
as a novel molecular target in some human cancers. Here, we show that PP2A 
inhibition is a common event in breast cancer and identified PP2A phosphorylation 
and deregulation SET and CIP2A as molecular contributing mechanisms to inactivate 
PP2A. Interestingly, restoration of PP2A activity after FTY720 treatment reduced cell 
growth, induced apoptosis and decreased AKT and ERK activation. Moreover, FTY720 
led to PP2A activation then enhancing doxorubicin-induced antitumor effects both 
in vitro and in vivo. PP2A inhibition (CPscore: PP2A phosphorylation and/or CIP2A 
overexpression) was detected in 27% of cases (62/230), and associated with grade 
(p = 0.017), relapse (p < 0.001), negative estrogen (p < 0.001) and progesterone 
receptor expression (p < 0.001), HER2-positive tumors (p = 0.049), Ki-67 expression 
(p < 0.001), and higher AKT (p < 0.001) and ERK (p < 0.001) phosphorylation. 
Moreover, PP2A inhibition determined shorter overall (p = 0.006) and event-free 
survival (p = 0.003), and multivariate analysis confirmed its independent prognostic 
impact. Altogether, our results indicate that PP2A is frequently inactivated in breast 
cancer and determines worse outcome, and its restoration using PP2A activators 
represents an alternative therapeutic strategy in this disease.
INTRODUCTION
Breast cancer is the most common diagnosed cancer 
and accounts for the majority of cancer-related deaths in 
women worldwide [1]. This is a very heterogeneous disease 
at both molecular and clinical levels and the conventional 
histopathological TNM staging criteria is still used to 
predict prognosis [2, 3]. Actually, breast cancer classification 
discriminates five different tumor subtypes and a normal 
breast-like group based on an immunohistochemical criteria 
that includes expression of estrogen (ER) and progesterone 
receptors (PR), and human epidermal growth factor receptor 
2 (HER2). Of importance, within this classification, 
the triple-negative subtype includes those cases with 
worst prognosis and represents a major challenge from a 
therapeutic perspective [4]. Therefore, it remains necessary 
to improve our knowledge about the molecular bases 
that governs breast cancer pathogenesis to develop more 
personalized and effective therapies that enhance patient 
outcomes and overcome resistance to standard chemotherapy 
treatments [5, 6].
The protein phosphatase 2A (PP2A) is a key tumor 
suppressor that regulates signaling pathways with a 
Oncotarget4300www.impactjournals.com/oncotarget
high relevance in human cancer [7–9]. Several different 
molecular mechanisms to inhibit PP2A have been described 
in cancer cells including alterations in PP2A subunits or 
deregulation of endogenous PP2A inhibitors such as SET 
and CIP2A [10, 11]. Interestingly, downregulation and low 
prevalent inactivating mutations affecting PP2A have been 
previously reported in breast cancer [12–15]. In addition, 
although the role of SET in breast cancer remains mostly 
unknown, it has been described high SET levels and low 
PP2A activity in the MCF-7 cell line [16], and the work 
by Switzer et al. [17] showed that COG112-mediated 
SET inhibition in the MDA-MB-231 breast cancer cells 
reduced AKT signaling and cell proliferation, indicating 
that SET could serve as a novel therapeutic target in 
these cancers. Furthermore, CIP2A has been reported to 
be associated with breast cancer aggressivity [18] and to 
modulate sensitivity of breast cancer cells to bortezomib 
and doxorubicin treatments [19, 20]. Moreover, it has 
been recently reported that CIP2A deficient mice are 
resistant to mammary tumorigenesis, the existence of a 
positive feedback loop involving CIP2A and E2F1 which 
defines senescence sensitivity of breast cancer cells [21], 
and the CIP2A modulation of mTORC1 and authophagy 
in this disease [22]. In this study, we show that PP2A is 
commonly inactivated in breast cancer and identify that 
CIP2A and SET overexpression together with PP2A 
hyperphosphorylation are key contributing mechanisms to 
inhibit PP2A in this disease. Of importance, we show that 
FTY720 treatment activates PP2A through decreasing its 
phosphorylation and CIP2A expression and then reduces 
cell growth and induces caspase-dependent apoptosis. 
Moreover, FTY720-induced PP2A activation led to 
changes in AKT and ERK activation status and potentiates 
doxorubicin antitumor effects in both parental and 
mammosphere-derived breast cancer cells. To determine 
its clinical relevance, we quantified SET, CIP2A and 
PP2A phosphorylation in a series of 230 breast cancer 
patients, observing that PP2A inhibition is a recurrent 
molecular event that determines shorter overall and event-
free survival. Interestingly, our results highlight that the 
use of PP2A activators alone or in combination with drugs 
such as doxorubicin could be a promising therapeutic 
alternative for treating an important subgroup of breast 
cancer patients.
RESULTS
Different PP2A activation levels occurs in 
breast cancer
We first analyzed the PP2A activation status in five 
cell lines representative of the different subtypes of breast 
cancer, observing that all of them showed a significant 
reduction of PP2A activity (Figure 1A). In order to 
investigate the molecular causes of this PP2A inhibition, 
we analyzed PP2A expression and phosphorylation levels 
on PP2A tyrosine-307 together with the expression of 
the endogenous PP2A inhibitors SET and CIP2A. Of 
importance, it has been reported that PP2Ac is inactive 
when tyrosine-307 is phosphorylated [23]. In concordance 
with the results showed by the PP2A activity assays, we 
found PP2A hyperphosphorylated together with SET and 
CIP2A markedly overexpressed in all the breast cancer 
cell lines analyzed (Figure 1B). To confirm their PP2A 
inhibitory function, CIP2A and SET depletion experiments 
were carried out in MDA-MB-231 and BT-474 cells, 
observing that both CIP2A and SET silencing led to an 
increased PP2A activity (Figure S1A, Figure S1B and 
Figure S1C). Altogether, these results would suggest that 
PP2A inhibition is a relevant alteration in breast cancer and 
indicate the simultaneous cooperation of several distinct 
molecular mechanisms to inhibit PP2A in this disease.
PP2A activation by FTY720 reduces cell viability 
in breast cancer
To clarify the biologic relevance of PP2A 
deregulation in breast cancer cells, we assessed whether an 
increase of PP2A activity could affect their cell viability. 
Thus, we treated the MDA-MB-231 and BT-474 cell lines 
with the PP2A activator FTY720 or vehicle (DMSO). 
These cell lines were chosen based on their CIP2A and 
SET overexpression levels (Figure 1B) and because they 
represent aggressive breast cancer phenotypes (MDA-
MB-231: triple negative; BT-474: HER-2). However, all 
the 5 breast cancer cell lines analyzed showed similar 
sensitivity to FTY720 treatment (IC50 range from 2.9 to 
8.5 μM; MDA-MB-231: 2.9 μM; BT-474: 8.5 μM; MCF-
7: 5.3 μM; SK-BR-3: 3.9 μM; MDA-MB-468: 4.1 μM).
Furthermore, quantification of PP2A activity by 
phosphatase assays confirmed that FTY720 led to PP2A 
activation in both MDA-MB-231 and BT-474 cell lines, 
observing around 1.5-fold increase in the PP2A activity 
(Figure 2A). As a control, we pretreated MDA-MB-231 and 
BT-474 cells with the PP2A inhibitor OA for 90 minutes, 
followed by incubation with FTY720 or vehicle for 
24 hours. OA was used at a concentration that inhibits PP2A 
but no other phosphatases [24], observing that FTY720-
induced PP2A activity was inhibited by OA (Figure 2A). 
To evaluate whether FTY720 is a specific PP2A activator 
we quantified PP2A and PP1 activities in MDA-MB-231 
and BT-474 cells after FTY720 treatment, observing that 
FTY720 was able to increase only PP2A activity. To confirm 
that OA is a specific PP2A inhibitor at this concentration, 
similar experiments were carried out (Figure S2).
To further investigate the biologic effect of the 
FTY720-induced PP2A activation in breast cancer, we 
assessed apoptosis measuring activity levels of caspase 3 
and 7. In concordance with its ability to activate PP2A 
and decrease cell viability FTY720 induced caspase-
dependent apoptosis, increasing caspase activity levels 
more than 5-fold in both MDA-MB-231 and BT-474 cells 
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in comparison with vehicle-treated cells. No differences 
were found in vehicle-treated cells pretreated with OA. 
However, OA markedly reduced FTY720-induced caspase 
activity (Figure S3A). Altogether, these results would 
indicate that PP2A activation by FTY720 treatment has a 
promising therapeutic value in breast cancer cells.
PP2A activation by FTY720 enhances antitumor 
activity of doxorubicin
Anthracyclines like doxorubicin are among the 
chemotherapy drugs used in breast cancer standard 
systemic therapy [6]. Interestingly, we found that 
doxorubicin-induced antitumor effects in the MDA-
MB-231 and BT-474 cell lines were markedly enhanced 
when cells were treated simultaneously with the PP2A 
activator FTY720 (Figure 3A). The microscope images 
obtained were in concordance with the results showed 
by MTS assays in both cell lines (Figure S3B). Chou-
Talalay analyses showed that the FTY720/doxorubicin 
combination has additive effects in MDA-MB-231 cells 
(Combination index [CI] = 0.99), and synergistic effects 
in BT-474 cells (CI = 0.87). Altogether, these results 
show that FTY720 treatment potentiates doxorubicin-
induced antitumor effects in breast cancer cells. To further 
confirm our hypothesis that PP2A activation sensitizes 
to doxorubicin treatment, we performed a genetic PP2A 
activation by overexpressing PP2A in MDA-MB-231 
and BT-474 cells, observing that doxorubicin showed 
significantly enhanced antitumor effects in those cells 
ectopically expressing PP2A (Figure S4). Finally, we 
analyzed the effect of FTY720 treatment in a MDA-MB-
231-derived clone with a doxorubicin resistance (in fold 
change compared to parental cells) of 1,92. Of importance, 
we observed that FTY720 was able to resensitize to 
doxorubicin MDA-MB-231 clones with an acquired 
resistance to this drug (Figure 3B).
We next evaluated mammosphere formation in BT-
474 cells, observing that both FTY720 and doxorubicin 
decreased mammosphere formation in both number and 
size of mammospheres formed. However, the combination 
of FTY720 with doxorubicin almost completely abolished 
the formation of mammospheres (Figures 3C and S5A). 
Of interest, 10-fold lower concentration of both drugs 
(1 μM) was used in mammosphere formation assays since 
higher concentrations totally impaired mammosphere 
Figure 1: The tumor suppressor PP2A is inhibited in breast cancer cell lines. (A) Quantification of PP2A activity and western 
blot showing levels of immunoprecipitated PP2A from the protein extracts used in the phosphatase assays. (B) Western blot analysis 
showing PP2A, phospho-PP2A, CIP2A and SET expression levels; *p < 0.05; **p < 0.01; N1–3: normal controls corresponding to normal 
mammary tissue samples obtained from Fundación Jiménez Díaz Biobank (Madrid, Spain).
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formation (Figure S5B). MDA-MB-231 cells were unable 
to form well-defined mammospheres. To further confirm 
these results on mammospheres already formed, we next 
performed mammosphere formation during 7 days and 
then treated well-defined BT-474-derived mammospheres 
with vehicle, FTY720 and doxorubicin alone or combined 
with FTY720. As expected, we found that FTY720 
enhanced doxorubicin-induced antitumor effects which 
confirmed our previous findings (Figure S6).
Western blot analysis showed that FTY720 
decreased phosphorylation of the PP2A targets AKT 
and ERK without affecting their expression (Figure 
3C). We observed that PP2A phosphorylation was 
negatively affected in FTY720-treated cells compared 
with vehicle-treated cells. Moreover, we found reduced 
CIP2A levels after FTY720 treatment whereas no changes 
were observed in SET expression. As expected, c-MYC 
levels decreased in correlation with CIP2A by FTY720 
(Figure 3D). We next extracted RNA from MDA-MB-231 
and BT-474 cells after treatment with vehicle or FTY720 
alone or combined with doxorubicin and quantified 
CIP2A and PP2A by real-time PCR. Interestingly, we 
show that CIP2A mRNA levels did not change after 
FTY720 treatment (Figure S7A), indicating that CIP2A 
downregulation is a post-translational event as well as 
reduced PP2A phosphorylation since both PP2A mRNA 
and protein expression remained without changes 
(Figure S7A and Figure 3D). Additionally, we have 
analyzed the effect of FTY720 treatment in MDA-MB-231 
cells ectopically expressing CIP2A. Interestingly, we 
observed that CIP2A overexpression restore basal levels 
of c-MYC together with AKT and PP2A phosphorylation 
(Figure S7B). Altogether, these results would indicate 
that the molecular mechanism of action of FTY720 in 
breast cancer cells involves PP2A activation through its 
dephosphorylation and CIP2A downregulation together 
with inhibition of AKT and ERK signaling.
In vivo evaluation of FTY720 alone and 
combined with doxorubicin shows promising 
antitumor effects
MDA-MB-231 xenografts were performed to 
evaluate in vivo the activity of FTY720 alone or in 
combination with doxorubicin. We observed that tumor 
growth were significantly reduced by both FTY720 
and doxorubicin treatments. Interestingly, FTY720 
significantly enhanced doxorubicin-induced antitumor 
effects, confirming our previous observations in vitro 
(Figure 4A). Tumor specimens collected at the end of the 
experiments were analyzed by immunohistochemistry 
(Figure 4B). In concordance with our in vitro results, 
FTY720 led to reduced CIP2A and p-PP2A expression. 
As expected, SET expression was not altered in any of the 
treatment regimens of the in vivo xenograft (Figure 4C). 
Although the highest effects were shown by the combined 
Figure 2: FTY720 impairs cell viability through PP2A activation. (A) Treatment with OA inhibits the FTY720-induced PP2A 
activity in MDA-MB-231 and BT-474 cells. (B) The impaired cell growth induced by FTY720 is restored by the treatment with OA.
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treatment, both FTY720 and doxorubicin treatments 
significantly reduced proliferation (phosphorylated H3) 
and enhaced apoptosis (cleaved caspase 3) (Figure 4C).
Prevalence of PP2A inhibition in human breast 
cancer and its association with molecular and 
phenotypic parameters
To investigate the prevalence and clinical 
significance of PP2A inhibition, we quantified SET, 
CIP2A and phosphorylated PP2A (p-PP2A) expression 
in a cohort of 230 patients with early breast cancer mainly 
treated with anthracyclin-based adjuvant chemotherapy. 
Patient characteristics are presented in Table S1 and 
immunohistochemical detections of CIP2A, p-PP2A and SET 
are shown in Figure 5A. CIP2A and p-PP2A were expressed 
mainly in the cytoplasm of cancerous cells and diffusely 
distributed in the tumor. Weak staining was also detected for 
both markers in stromal cells (i.e. fibroblasts, lymphocytes 
and endothelial cells). SET was exclusively observed in 
malignant cells and with a predominantly nuclear location.
High p-PP2A levels were observed in 20% of 
cases (46/230), whereas SET and CIP2A were found 
overexpressed in 13.5% (31/230) and 17.8% of cases 
(41/230) respectively. Of relevance, SET overexpression 
was significantly associated and always detected in 
combination with high p-PP2A and/or CIP2A (p < 
0.001; only 1 out of the 31 SET overexpressed cases 
was negative for p-PP2A and CIP2A) (Table S2). In 
addition, it was the only PP2A inhibitor marker studied 
without significant prognostic value in our cohort (p = 
0.085). These observations prompted us to analyze the 
PP2A phosphorylation/inhibition status in breast cancer 
cells using a “CPscore” in which value 0 was defined 
by those breast cancer patients without altered p-PP2A 
and CIP2A, value 1 for those ones with high p-PP2A 
or CIP2A overexpressed, and value 2 for the subgroup 
of breast cancer cases with high p-PP2A and CIP2A 
Figure 3: FTY720-induced PP2A activation potentiates antitumor effects of doxorubicin in breast cancer cells. (A) MTS 
assays showing cell growth after FTY720 treatment in combination with doxorubicin in MDA-MB-231 and BT-474 cells. Cells treated 
with vehicle (DMSO) were used as controls. (B) MTS analysis showing that FTY720 resensitizes to doxorubicin MDA-MB-231 cells with 
doxorubicin acquired resistance. (C) Evaluation of mammosphere formation capability in BT-474 cells after doxorubicin and FTY720 
treatments. (D) Western blot analysis showing the molecular effects induced after FTY720 treatment in combination with doxorubicin in 
MDA-MB-231 and BT-474 cells; *p < 0.05; **p < 0.01.
Oncotarget4304www.impactjournals.com/oncotarget
overexpression. Thus, we observed that high CPscore 
associated with tumor grade (p = 0.017), absence of ER 
(p < 0.001) and PR expression (p < 0.001), and HER2 
amplification (p = 0.049). Importantly, we also found high 
CPscore in those patients with higher tumor proliferation 
rates measured using Ki-67 (p < 0.001). Finally, we 
observed that PP2A phosphorylation/inhibition positively 
correlated with higher AKT (p < 0.001) and ERK 
(p < 0.001) phosphorylation levels in tumor cells (Figure 
S8A). Association between CPscore and molecular and 
clinical parameters are included in Table 1.
Clinical significance of PP2A phosphorylation/
inhibition in human breast cancer
Clinical follow-up data were available for all the 230 
patients included in the study, with a median of age of 58 years 
(range: 26–90). Of relevance, high CPscore was found in those 
patients who relapsed (p < 0.001). Additionally, the subgroup 
of patients with high CPscore showed a substantially shorter 
OS (hazard ratio (HR) 1.7; 95% CI, 0.8–3.6; p = 0.006) 
and EFS (HR 1.3; 95% CI, 0.7–2.3; p = 0.003) (Figure 5B 
and Figure 5C). Moreover, we correlated CPscore with OS 
and EFS in those 99 breast cancer patients who received 
adjuvant anthracycline-based chemotherapy from our cohort 
of 230 cases. As expected, we observed that high CPscore 
was negatively associated with OS (p = 0.074) and EFS 
(p = 0.124). In this case, significance was not achieved 
probably due to the lower number of patients included in 
this subgroup (Figure S8B). Multivariate Cox analysis 
demonstrated that CPscore is an unfavorable independent 
factor associated with OS (HR 1.8; 95% confidence interval 
(CI), 1.2–2.6; p = 0.004) (Table 2) and EFS (HR 1.8; 95% CI, 
1.2–2.7; p = 0.002) (Table S3) in early breast cancer.
PP2A phosphorylation/inhibition determines 
response to doxorubicin in human breast cancer 
patients
In order to provide clinical evidences to our 
hypothesis that PP2A determines doxorubicin resistance, 
we analyzed the PP2A inhibition status (CPscore) in an 
Figure 4: In vivo analysis of antitumor effects of FTY720 alone or combined with doxorubicin. (A) Tumor growth and 
statistical analysis between control, FTY720, doxorubicin and FTY720+doxorubicin groups of treatment (B) Immunohistochemical 
detection of CIP2A, SET, p-PP2A, p-Histone H3 and cleaved-Caspase 3 expression in tumor samples from the different groups of treatment. 
(C) Evaluation of differential expression of CIP2A, SET, p-PP2A, p-Histone H3 and cleaved-Caspase 3.
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Table 1: Association of PP2A phosphorylation/inhibition with molecular and clinical parameters 
in 230 BC patients
No. Cases No. CPscore 0 (%) No. CPscore 1 (%) No. CPscore 2 (%) p
CPscore 230 168 (73.0) 37 (16.1) 25 (10.9)
T 230 168 37 25 0.552
1 113 83 (49.4) 19 (51.4) 11 (44.0)
2 93 65 (38.7) 16 (43.2) 12 (48.0)
3 22 19 (11.3) 1 (2.7) 2 (8.0)
4 2 1 (0.6) 1 (2.7) 0 (0.0)
N 230 168 37 25 0.077
0 134 104 (61.9) 17 (45.9) 13 (52.0)
1 52 31 (18.5) 14 (37.8) 7 (28.0)
2 26 22 (13.1) 3 (8.1) 1 (4.0)
3 18 11 (6.5) 3 (8.1) 4 (16.0)
Stage 228 167 37 24 0.168
1 84 68 (40.7) 9 (24.3) 7 (29.2)
2 101 66 (39.5) 21 (56.8) 14 (58.3)
3 43 33 (19.8) 7 (18.9) 3 (12.5)
Grade 230 168 37 25 0.017
1 33 29 (17.3) 1 (2.7) 3 (12.0)
2 108 84 (50.0) 14 (37.8) 10 (40.0)
3 89 55 (32.7) 22 (59.5) 12 (48.0)
Morphological type 104 83 15 6 0.754
IDC 97 76 (91.6) 15 (100.0) 6 (100.0)
ILC 6 6 (7.2) 0 (0.0) 0 (0)
Others 1 1 (1.2) 0 (0.0) 0 (0)
ER 230 168 37 25 <0.001
Negative 90 52 (31.0) 18 (48.6) 20 (80.0)
Positive 140 116 (69.0) 19 (51.4) 5 (20.0)
PR 230 168 37 25 <0.001
Negative 107 65 (38.7) 20 (54.1) 22 (88.0)
Positive 123 103 (61.3) 17 (45.9) 3 (12.0)
HER2 230 168 37 25 0.049
Negative 157 121 (72.0) 24 (64.9) 12 (48.0)
Positive 73 47 (28.0) 13 (35.1) 13 (52.0)
Hormonal status 222 161 36 25 0.115
Premenopausal 59 41 (25.5) 14 (38.9) 4 (16.0)
Postmenopausal 163 120 (74.5) 22 (61.1) 21 (84.0)
Relapse 230 168 37 25 <0.001
No 158 126 (75.0) 23 (62.2) 9 (36.0)
(Continued )
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independent set of 35 patients with locally advanced 
breast cancer who received neoadjuvant anthracycline-
based chemotherapy. Patient characteristics are shown 
in Table S4. The mean time from the diagnostic biopsy 
to the beginning of chemotherapy was 20.5 days (range 
1–47 days). During that period of time, patients underwent 
standard clinical and radiological tumor staging. Patients 
received a median of 4 cycles of chemotherapy (range 2–6 
No. Cases No. CPscore 0 (%) No. CPscore 1 (%) No. CPscore 2 (%) p
Yes 72 42 (25.0) 14 (37.8) 16 (64.0)
Ki-67 230 168 37 25 <0.001
Low 151 123 (73.2) 14 (37.8) 14 (56.0)
High 79 45 (26.8) 23 (62.2) 11 (44.0)
p-ERK 211 152 34 25 <0.001
No 150 134 (88.2) 12 (35.3) 4 (16.0)
Yes 61 18 (11.8) 22 (64.7) 21 (84.0)
p-AKT 220 161 34 25 <0.001
No 147 128 (79.5) 16 (47.1) 3 (12.0)
Yes 73 33 (20.5) 18 (52.9) 22 (88.0)
IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; ER: estrogen receptor; PR: progesterone receptor; HR: 
hormone receptor.
Figure 5: Clinical significance of PP2A phosphorylation/inhibition in breast cancer. (A) Immunohistochemical detection of 
CIP2A, p-PP2A and SET showing positive and negative staining. The line shows 25 μm. Magnification x400. Kaplan-Meier analyses of 
overall survival (B) and event-free survival (C) in a cohort of 230 breast cancer patients.
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cycles). All patients received an anthracycline-containing 
chemotherapy schedule. The overall clinical response rate 
(RR) (cCR and cPR) was 71.4%. After recovering from the 
effects of chemotherapy, the patients underwent surgery. 
The mean time between the last dose of chemotherapy 
and acquisition of the post-chemotherapy specimen from 
surgery was 31.2 days (range 7–61 days). Nine patients 
(25.7%) achieved a pathological complete response in the 
surgery specimen according to histopathological evaluation. 
Interestingly, we observed that PP2A phosphorylation/
inhibition negatively correlates with both clinical (p = 0.01) 
and pathological response (p < 0.01) (Table S5).
To further confirm our hypothesis, we also 
determined CPscore, phosphorylated H3 and cleaved 
caspase 3 in 25 fresh breast cancer specimens treated ex 
vivo with doxorubicin. The results showed that the CPscore 
inversely correlated with proliferation (p < 0.01) and 
apoptosis activation (p < 0.01) after doxorubicin treatment 
(Figure S8C). Therefore, these results reinforce our 
clinical results regarding to the impact of the CPscore with 
doxorubicin resistance in breast cancer, and the potential 
therapeutic value of FTY720-induced PP2A activation in 
combination with doxorubicin in breast cancer.
DISCUSSION
PP2A is a tumor suppressor that regulates signaling 
pathways crucial for maintaining tumor cell properties [7–9]. 
We report here that PP2A inhibition is a frequent event in 
breast cancer and identified PP2A hyperphosphorylation 
together with SET and CIP2A overexpression as molecular 
mechanisms that cooperate to inactivate this phosphatase. 
Of importance, restoration of PP2A activity after FTY720 
treatment reduced cell viability, induced caspase-dependent 
apoptosis and inactivated AKT and ERK by decreasing 
their phosphorylation status. We also found that FTY720-
induced PP2A activation potentiated doxorubicin antitumor 
effects in breast cancer cells both in vitro and in vivo. 
Moreover, patients with PP2A phosphorylation/inhibition 
had significantly worse clinical outcome and multivariate 
analysis, suggesting that PP2A phosphorylation/inhibition 
has an independent prognostic value for overall and event-
Table 2: Univariate and multivariate cox analyses in the cohort of 230 BC patients (overall survival 
analysis)
Univariate OS analysis Multivariate OS Cox analysis
95% CI 95% CI
HR Lower Upper Significance HR Lower Upper Significance
Stage 0.003 0.909
1.000 1.000
1.951 1.262 to 3.017 0.958 0.463 to 1.985
Grade 0.029 0.115
1.000 1.000
1.742 1.060 to 2.864 1.565 0.896 to 2.732
T 0.001 0.115
1.000 1.000
1.938 1.297 to 2.897 1.637 0.887 to 3.022
N <0.001 0.055
1.000 1.000
1.656 1.270 to 2.160 1.379 0.993 to 1.915
Molecular subtype 0.813 0.327
1.000 1.000
1.047 0.717 to 1.528 0.808 0.528 to 1.237
CPscore 0.003 0.003
1.000 1.000
1.768 1.221 to 2.560 1.830 1.234 to 2.716
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free survival in breast cancer patients. Therefore, our 
results demonstrate that PP2A inhibition is a common event 
with a high clinical relevance in breast cancer and that the 
use of PP2A activators such as FTY720 has a potential 
therapeutic value and could represent an alternative 
therapeutic strategy for treating breast cancer patients.
Despite some data in the literature suggest a 
potential importance of PP2A inactivation in breast 
cancer, its clinical and molecular significance still need to 
be fully clarified. Although functional PP2A inactivating 
alterations have been previously reported [12–15, 25] their 
low prevalence suggests that this is not a key mechanism 
to inhibit PP2A. However, the mutational status of PP2A 
should be studied to evaluate their potential contribution to 
the reduced PP2A activity observed in breast cancer cells. 
Thus, we could further clarify whether the observed PP2A 
inhibition is the result of SET or CIP2A overexpression or 
inhibiting mutations of PP2A. Furthermore, several works 
described a potential relevant role of the PP2A inhibitor 
CIP2A. Thus, we observed a reduced PP2A activity in all 
the five breast cancer cell lines analyzed, identifying PP2A 
hyperphosphorylation and SET and CIP2A overexpression 
in all cases, which prompted us to hypothesize that these 
could be relevant contributing mechanisms to inhibit PP2A 
in breast cancer. Interestingly, PP2A mutations were not 
found in a recently published work after analyzing 4 breast 
cancer cell lines and an additional set of 25 cell lines from 
other tumors. Moreover, the authors studied publically 
available datasets (cBioPortal) and reported that PP2A 
activation status could be deregulated in more than 50% of 
basal breast cancer tumors due to alterations affecting PP2A 
subunits or deregulation of endogenous PP2A inhibitors 
such as SETBP1, SET or CIP2A [26]. However, it has 
been reported that SETBP1 binds and protects SET from 
the protease cleavage then inhibiting PP2A [27]. Therefore, 
it remains necessary to analyze whether SET is proteolyzed 
in breast cancer before concluding that SETBP1 could 
contribute to PP2A inhibition in this disease.
Reversible methylation of PP2A by leucine carboxyl 
methyltransferase 1 (LCMT-1) and protein phosphatase 
methylesterase 1 (PME-1) has been reported as a relevant 
PP2A regulatory mechanism [28]. However, their status in 
breast cancer still remains unexplored and further studies 
are needed to clarify the potential relevance of PP2A 
methylation in this disease. Furthermore, considering 
that the PP2A regulatory subunit is determining both the 
substrate and the location of the PP2A complex [9], it 
would be very interesting to study the different families of 
PP2A regulatory subunits to properly clarify their status 
and relevance in breast cancer. Moreover, future studies 
evaluating PP2A phosphorylation after knock-down of 
SET or CIP2A are warranted to assess their relevance in 
regulating PP2A activity in breast cancer.
FTY720 is a FDA-approved immunosuppressor 
used in multiple sclerosis treatment, which has shown 
promising preclinical effects in several human cancers [10, 
29, 30]. Thus, we evaluate the potential therapeutic value 
of PP2A activation using FTY720 to treat breast cancer 
cells and observed a significant decrease of cell growth 
and induction of caspase-dependent apoptosis in both 
MDA-MB-231 and BT-474 cells, in concordance with the 
FTY720-mediated antitumor properties previously reported 
[26, 31, 32]. Importantly, we confirmed by PP2A assays that 
those FTY720-mediated effects were dependent on PP2A 
activation since pretreatment with the PP2A inhibitor OA 
almost totally restored these FTY720 induced effects. The 
fact that cell viability was not completely restored when 
cells were treated with FTY720 combined with OA is 
probably due to an additional FTY720-induced toxicity as 
previously reported in other tumor models such as colorectal 
cancer or acute myeloid leukemia [11, 30]. Therefore, the 
contribution of PP2A to FTY720 biological effects should 
be fully clarify in future studies using PP2A siRNAs or 
dominant active constructs. These observations are of high 
relevance suggesting the potential use of different PP2A 
activating drugs for breast cancer treatment [33].
Furthermore, FTY720 has been described to enhance 
the effects of sunitinib malate [34] and to increase radiation 
sensitivity of breast cancer cells [35]. Doxorubicin is an 
anthracycline currently used in breast cancer standard 
chemotherapy [6]. Thus, we next evaluated whether FTY720 
could modulate doxorubicin sensitivity of breast cancer 
cells, observing that doxorubicin-induced antitumor effects 
were markedly enhanced after FTY720-induced PP2A 
activation. Moreover, we observed that FTY720 was able 
to resensitize to doxorubicin MDA-MB-231 clones with an 
acquired resistance to this drug. This observation together 
with the results obtained by the ex vivo experiments and 
the fact that CPscore determined response to neoadjuvant 
doxorubicin would indicate that PP2A activation is able to 
overcome doxorubicin resistance in breast cancer cells.
In addition, FTY720 led to reduced p-PP2A and 
CIP2A levels then enhancing PP2A activity. Of interest, 
CIP2A has been reported to modulate sensitivity of breast 
cancer cells to bortezomib and doxorubicin treatments 
[19, 20]. These data would indicate that the effect of 
FTY720 potentiating sensitivity of breast cancer cell 
to doxorubicin is probably via CIP2A downregulation 
and suggest a potential enhanced antitumor efficacy of a 
combination between FTY720 and bortezomib that should 
be explored. Moreover, CIP2A has been reported as a useful 
predictive marker of response to vinca alkaloid-containing 
chemotherapy in HER2-negative breast cancer patients 
[21]. Unexpectedly, a recent published work reported that 
FTY720 decreased sensitivity of SK-BR-3 cells to lapatinib, 
a compound used as HER2 targeted therapy in breast 
cancer. However, FTY720 was used at 2.5 μM (vs 10 μM 
here) during 24 hours and the authors claimed that FTY720 
alone did not significantly affect the growth of the SK-
BR-3 cells (2.5% growth inhibition) [36]. Besides, PP2A 
activity assays after FTY720 treatment are missed and one 
would expect lower PP2A activation with 2.5 μM than 
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with 10 μM. Altogether, further studies to fully clarify the 
molecular mechanisms by with FTY720 contributes to the 
acquisition of a lapatinib resistant phenotype are warranted.
On the other hand, CIP2A inhibits PP2A-mediated 
c-MYC dephosphorylation/degradation [37], and our 
results show a correlation between CIP2A and c-MYC 
levels after FTY720 treatment. Additionally, CIP2A 
signature reveals the c-MYC dependency of CIP2A-
regulated phenotypes and its association with breast cancer 
subtypes [38]. In concordance with our findings, a recent 
work has shown that both CIP2A and SET are frequently 
co-overexpressed with c-MYC in breast cancer cell lines 
[39]. Treatment with OP449, a novel SET inhibitor, 
decreases the tumorigenic potential of breast cancer cells, 
and SET inhibition was proposed as the best therapeutic 
strategy to activate PP2A – no known inhibitors of CIP2A 
have been described – as it could be an antitumor strategy 
to post-translationally target c-MYC. In contrast, we 
proved that extended inhibition of CIP2A expression, 
SET-induced PP2A inhibition and PP2A-phosphorylation 
by FTY720 treatment caused a deeply antitumoral effect in 
breast cancer cells. FTY720 binds SET and inhibits SET-
PP2A interaction then leading to PP2A reactivation [40]. 
However, the drug does not affect SET protein expression 
as we observed in this work. Further, we also observed that 
FTY720 treatment led to reduced CIP2A expression and 
PP2A phosphorylation without changes in mRNA levels 
This post-translational FTY720 effect on CIP2A and PP2A 
phosphorylation should further be investigated in future 
works. Thus, we could better understand why this drug is 
a potent PP2A activator and also the potential antagonistic 
effects of FTY720 with other compounds as those observed 
with lapatinib [36] or SET-binding drugs [41].
The clinical validation in our cohort supports 
new therapeutic possibilities in breast cancer patients 
for a wide-spectrum drug like FTY720. In addition, we 
found reduced phosphorylation of the PP2A targets AKT 
and ERK after FTY720 treatment and, interestingly, we 
validated these results in a large series of early breast 
cancer patients, observing a significant correlation 
between PP2A phosphorylation/inhibition through the 
CPscore and AKT and ERK phosphorylation levels. Since 
SET overexpression was always detected in combination 
with high p-PP2A and/or CIP2A (except 1 out of the 
31 SET overexpression cases) and had no significant 
prognostic value in our cohort, we used a CPscore in 
which value 0 was assigned to absence of p-PP2A and 
CIP2A, value 1 to high p-PP2A or CIP2A overexpression, 
and value 2 to those breast cancer cases with high p-PP2A 
and CIP2A overexpression. In fact, it has been reported 
higher p-PP2A in later stages of breast cancer progression 
and its prognostic value that was not determined [42]. 
Another study showed CIP2A associated with breast 
cancer aggressiveness [18]. PP2A has been previously 
reported to positively regulate expression levels of 
estrogen receptor alpha (ER) [43] and we observed that 
high CPscore significantly correlated with negative 
ER expression in our cohort. Importantly, absence of 
ER expression determines poor prognosis and lack of 
response to hormonal therapy and it would be indicating 
that PP2A inhibition confers poor outcome to breast 
cancer patients. Of mention, a recent work described that 
estradiol enhances CIP2A expression and showed higher 
CIP2A levels in ER-positive tissues than in ER-negative 
tissues [44]. These observations are not consistent with 
the previous observations by Keen [43] since CIP2A is 
a well established PP2A inhibitor. In fact, our results 
shows that both CPscore (as mentioned above) (p < 0.001) 
and CIP2A (p < 0.001) (data not shown) significantly 
associates with ER-negative tumors supporting that PP2A 
inhibition negatively correlates with ER expression. 
Interestingly, high CPscore was also associated with 
negative PR expression in our cohort which suggests 
a potential role of PP2A regulating PR expression that 
should be experimentally confirmed in future studies. 
Furthermore, we found a direct correlation between PP2A 
inhibition and HER2 positive tumors which is consistent 
with a previous work which described that p-PP2A is 
positively modulated by HER2 signaling pathway [43]. 
However, we unexpectedly observed that p-PP2A showed 
lower association with HER2 (p = 0.056) in our cohort 
than CPscore with HER2 (p = 0.049), and these results 
could be explained by a potential loop regulation between 
PP2A and HER2. Further studies are needed to clarify 
this point. Finally, to investigate the potential clinical 
relevance of PP2A phosphorylation/inhibition we studied 
a cohort of 230 breast cancer patients. Importantly, higher 
CPscore determined significantly shorter OS and EFS and 
multivariate analysis showed that PP2A phosphorylation/
inhibition is a recurrent alteration with an independent 
prognostic value in breast cancer. However, it remains 
necessary to further analyze the clinical value of this 
CPscore in prospective studies focused on individual 
breast cancer molecular subtypes.
In conclusion, our results highlight that PP2A 
inhibition is a common event with high molecular 
and clinical relevance in breast cancer. Moreover, the 
high prevalence of this alteration suggests that PP2A 
hyperphosphorylation and CIP2A overexpression 
represent key mechanisms to inhibit PP2A in breast 
cancer, and our proposed CPscore would serve to define a 
subgroup of patients who might benefit from the inclusion 
of PP2A activators such as FTY720 in anticancer protocols 
for treating breast cancer patients alone or combined with 
an anthracycline-based chemotherapy backbones.
METHODS
Cell cultures
MDA-MB-231 (ATCC HTB-26), MDA-MB-468 
(ATCC HTB-132) and SK-BR-3 (ATCC HTB-30) were 
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cultured in DMEM/F12 (Sigma Aldrich) with 10% fetal 
bovine serum (FBS) (Life technologies); MCF-7 (ATCC 
HTB-22) in DMEM with 10% FBS; and BT-474 (ATCC 
HTB-20) in DMEM/F12 with 10% FBS and insulin 
(0.01 μg/ml). Cell lines were grown as monolayers at 37°C 
in a 5% CO2 atmosphere. Media were supplemented with 
L-glutamine (2 nM) (Gibco), penicillin G (100 U/ml), 
and streptomycin (100 μg/ml) (Gibco). Cells were 
purchased from American Type Culture Collection 
(ATCC) and authenticated (LGC Standards). Reagents: 
doxorubicin (10 μM) (Sigma Aldrich), okadaic acid (OA) 
(2.5 nM) and FTY720 (10 μM) (Calbiochem). To generate 
doxorubicin-resistant cells, MDA-MB-231 cells were 
cultured in the presence of increasing doses of doxorubicin 
(three subculturing cycles per concentration), starting at 
0.5 μM. In order to assess the evolution of resistance, we 
determined the IC50 after every doxorubicin concentration 
point, by using an MTS assay (Promega) at 24 h of 
treatment. The resistance of every doxorubicin-resistant 
clone was defined as the ratio between resistant and 
parental cells IC50 values.
Patient samples
Surgical resection specimens from primary breast 
tumors were obtained from Parc de Salut Mar Biobank 
(MARBiobanc, Barcelona, Spain), Fundación Jiménez 
Díaz Biobank (Madrid, Spain) and Valencia Clinic 
Hospital Biobank (Valencia, Spain). Tumor specimens 
from formalin-fixed paraffin-embedded (FFPE) blocks 
were retrospectively selected from consecutive breast 
cancer patients diagnosed between 1998 and 2000, 
which had the following criteria: infiltrating carcinomas, 
operable, no neoadjuvant therapy, enough available 
tissue and clinical follow-up. TNM (tumor–node–
metastasis) staging was classified using the American 
Joint Committee on Cancer (AJCC) staging system. 
Histological grade was defined according Scarff–Bloom–
Richardson modified by Elston criteria [45]. ER and PR 
were determined by immunohistochemistry (IHC) (SP1 
and PgR636 clones, respectively; Dako, Carpinteria, 
CA) establishing positivity criteria in > 1% of nuclear 
tumor staining [46]. HER2 amplification was assayed 
by FISH (Pathvysion; Abbott Laboratories, Abbott Park, 
IL) [47]. Ki-67 was studied by IHC (MIB1 clone; Dako) 
[48]. Clinical data were collected from medical clinical 
records by oncologists. Representative areas of each 
tumor were carefully selected and three tissue cores (1 mm 
diameter) were obtained using a TMA workstation (T1000 
Chemicon).
In addition, we included in the study an independent 
series of 35 patients with locally advanced breast cancer 
who had been treated with neoadjuvant chemotherapy 
from FJD-Biobank and pre-chemotherapy diagnostic 
core needle biopsies were achieved. Pre-treatment tumor 
specimens were histologically evaluated. As a part of the 
established routine protocol, ER, PR, HER2 and Ki67 
were evaluated by IHC and HER2 amplification was 
determined by FISH. High proliferation in breast cancer 
based on Ki67 labelling by IHC was defined following 
the 13th St Gallen International Breast Cancer Conference 
(2013) criteria based on a threshold ≥ 20% of proliferation 
[49]. Clinical data and follow-up were obtained from 
review of the patients’ medical records. Pre-treatment 
patient staging was classified using the American Joint 
Committee on Cancer (AJCC) staging system for breast 
cancer. Clinical tumor response to primary chemotherapy 
was evaluated according to the International Union 
Against Cancer Criteria [50]. A clinical complete 
response (cCR) was defined as the disappearance of all 
detectable malignant disease within the breast by physical 
examination. A reduction greater than 50% in the product 
of the two maximum perpendicular diameters of the 
tumor was classified as clinical partial response (cPR). 
Clinical progressive disease (cPD) was considered as an 
increase of at least 25%. Clinical stable disease (cSD) 
was defined when clinical breast cancer response did not 
meet the criteria for cCR, cPR or cPD. Post-chemotherapy 
specimens were evaluated for pathological response. A 
pathological complete response (pCR) was defined as 
no histological evidence of invasive disease in the tumor 
specimen [51].
Ex vivo models
Tissue slices larger than 1.5 cm from fresh surgical 
specimens of patients newly diagnosed with invasive 
breast cancer were obtained to add ex vivo doxorubicin and 
assess molecular effects [52]. The samples were processed 
in sterile conditions immediately after surgical resection. 
Incubation was performed in 24-well plates at 37°C in 
a constant atmosphere of 5% CO2 for 24 hours. At 24 
hours, the specimens were fixed in 10% neutral-buffered 
formalin for 16 hours at room temperature and embedded 
in paraffin under vacuum conditions. These specimens 
were assayed for molecular markers as described in the 
IHC section.
Western blot analysis
Protein extracts were isolated using TRIzol Reagent 
(Invitrogen) following manufacturer’s indications, 
clarified (12,000xg, 15min, 4°C), denatured and subjected 
to SDS-PAGE and Western-blot. Antibodies: rabbit 
polyclonal anti-SET (Abcam), rabbit monoclonal anti-
PP2AY307 (Epitomics), rabbit polyclonal anti-AKT, rabbit 
polyclonal anti-ERK1/2 (Cell Signaling Technology), 
rabbit polyclonal anti-pAKT, rabbit poly-clonal anti-
pERK1/2 (Santa Cruz Biotechnology), rabbit polyclonal 
anti-CIP2A, and mouse monoclonal anti-β-Actin (Sigma). 
Proteins were detected with the appropriate secondary 
antibodies conjugated to alkaline phospatase (Sigma) by 
chemiluminescence using Tropix CSPD and Tropix Nitro 
Block II (Applied Biosystems).
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Proliferation assay and cell viability
Cell proliferation was measured in triplicate wells 
by MTS assay in 96-well plates using the CellTiter 
96 AQueous One Solution Cell Proliferation Assay 
(Promega), following the manufacturer’s indications.
PP2A phosphatase activity assays
Protein extracts were isolated using TRIzol Reagent 
(Invitrogen). PP2A assays were performed with 50 μg 
protein extracts using a PP2A immunoprecipitation 
phosphatase assay kit (Millipore) and following 
the manufacturer’s instructions. Briefly, PP2A was 
immunoprecipitated using 4 μg of PP2A antibody and 25 μl 
Protein A agarose slurry, both supplied by the kit. After 2 
h of incubation in constant rocking, samples were washed 
3 times with TBS 1X followed by one additional wash with 
a ser/thr assay buffer also provided by the kit. Next, 60 μl 
of a diluted phosphopeptide at 750 μM and 40 μl of ser/thr 
assay buffer were added, and the mix was incubated for 
5 min at 30°C in a shaking incubator, and then 25 μl of 
the mix was transferred into each well of a 96-well plate. 
Each measurement was performed in triplicates. 100 μl of 
Malachite Green Detection Solution was added, and the mix 
was incubated for 15 min at room temperature. Absorbance 
at 650 nm was used to calculate the amount of phosphate 
released (pmol) using a standard curve (0–2000 pmol).
Analysis of caspase activation
Quantification of caspase 3/7 activities was carried 
out using the caspase Glo-3/7 assay kit (Promega), 
following the manufacturer’s indications. Differences 
in caspase-3/7 activity are expressed as fold-change in 
luminescence.
Mammospheres
For the generation of mammospheres, 10000 
cells were plated in 6-well ultra-low attachment plates 
(Corning). BCCL cells were grown in serum-free medium 
DMEM/F12+GlutMAXTM-I (Gibco) containing 1% N2 
(Gibco), 2% B27 (Gibco), 20 ng/ml human FGF (Sigma) 
and 50 ng/ml EGF (Sigma). After 7 days, plates were 
analyzed for mammosphere formation.
Quantitative real-time RT-PCR
Total RNA extracts were isolated with TRIzol 
Reagent (Invitrogen) following manufacturer’s 
indications. RNA purity and integrity were assessed by 
spectrophotometric determination (NanoDrop ND-2000, 
NanoDrop Technologies, USA). Then, RNA was reversely 
transcribed to cDNA using Transcriptor Universal cDNA 
Master (Roche Life Science). cDNA amplification was 
done in a 7500 Fast Real-Time PCR System (Applied 
Biosystems) at 40 cycles, and using TaqMan Gene 
Expression Assays specific for CIP2A and PP2A (Applied 
Biosystems). GAPDH was used as internal control. 
Relative gene expression was calculated according to the 
comparative cycle threshold (Ct) method.
In vivo animal model
All animal work was conducted as per the Barcelona 
Biomedical Research Park (PRBB) Institutional Animal 
Care and Scientific Committee guidelines. Briefly, 46-
week old female Balb/C nude mice were subcutaneously 
inoculated in their flank with 10 x 106 MDA-MB-231 
cells mixed with Matrigel as previously described [53]. 
Tumor growth was measured twice a week. Mice bearing 
subcutaneous 100–150 mm3 tumors were distributed 
homogenously into four groups of 10 mice each. The first 
group received saline vehicle intraperitoneally (i.p.) with 
no active drugs. In the second group, doxorubicin (2 mg/kg 
in saline) was inoculated i.p. twice a week [54]. In the 
third group, FTY720 (10 mg/kg in saline) was inoculated 
i.p. every two days [31]. The last group received the 
combination of both drugs at the same doses. At the end of 
the experiment, tumors were harvested and formalin-fixed.
Immunohistochemistry
Immunostainings were performed on tissue 
sections (3 μm) obtained from FFPE tumors as previously 
described [55]. Briefly, heat antigen retrieval was 
performed in pH9 EDTA-based buffer (Dako) and slides 
were incubated with same primary antibodies against 
CIP2A, SET p-PP2A, p-AKT or p-ERK [50], followed 
of appropriate anti-Ig horseradish peroxidase-conjugated 
polymer (Flex+, Dako). Sections were visualized with 
3,3’-diaminobenzidine as a chromogen. All stainings were 
performed in a Dako Autostainer. Sections incubated with 
normal non-immunized rabbit immunoglobulins were 
used as negative controls. As positive control, sections of 
breast tumor with known expression of targets were used. 
Antibody sensitivity was calculated in a range of crescent 
dilutions of primary antibody (CIP2A: 1:20–1:200, SET: 
1:100–1:5000, p-PP2A: 1:200–1:2000, p-AKT: 1:1–1:100, 
p-ERK: 1:50–1:500). Specificity was confirmed in a set of 
paired fresh frozen and FFPE samples were processed by 
western blot and IHC. Antigen preservation in tissues was 
confirmed assaying for expression of phospho-tyrosines 
using a monoclonal antibody to tyrosine-phosphorylated 
proteins (clone 4G10, 1:500, Millipore). Only the 
membrane of epithelial cells, but not stromal cells, was 
evaluated for CIP2A, SET and p-PP2A expression blinded 
to clinical data was evaluated by two investigators (FR 
and SZ). A semiquantitative histoscore (Hscore) was 
calculated by estimation of the percentage of tumor cells 
positively stained with low, medium, or high staining 
intensity. The final score was determined after applying a 
weighting factor to each estimate. The formula used was 
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Hscore = (low %) × 1 + (medium %) × 2 + (high %) × 3, 
and the results ranged from 0 to 300.
Statistical analysis
Statistical analyses were performed using SPSS 
20 for windows (SPSS Inc, Chicago Illinois). Overall 
survival (OS) was defined as the time from diagnosis 
to the date of death from any cause or last follow-
up. Event-free survival (EFS) was defined as the time 
from diagnosis until first event, in which relapse at any 
location, death or end of follow-up were considered 
events. Kaplan-Meier method and survival comparisons 
were done with the log-rank test. The Cox proportional 
hazards model was adjusted taking into consideration 
significant parameters in univariate analysis. A p-value 
less than 0.05 was considered statistically significant. 
Receiver operating curve (ROC) was used to determine 
the optimal cutoff point based on progression end point 
for p-PP2A, SET and CIP2A expression as previously 
described [56]. This work was carried out in accordance 
with Reporting Recommendations for Tumor Marker 
Prognostic Studies (REMARK) guidelines [57]. Analysis 
of experimental conditions was done by paired t-test. All 
the statistical tests were conducted at two sided 0.05 level 
of significance. Chou-Talalay analysis was performed 
using the CompuSyn Software (ComboSyn, Inc) and CI 
was used to determine additive/synergism calculations 
between FTY720 and doxorubicin treatments. CI< 
0.90, 0.90 < CI < 1.10 and CI> 1.10 were considered, 
respectively, synergistic, additive and antagonistic effects.
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